Inmune Bio (INMB) Share-based Compensation Growth (3y) (2021 - 2026)
Inmune Bio (INMB) Share-based Compensation Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.91% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 17.49% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.95% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.55% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 7.39% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 30.98% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | 56.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.20% |
| Mar 31, 2026 | 69.11% |
| Dec 31, 2025 | -7.19% |
| Sep 30, 2025 | 60.39% |
| Jun 30, 2025 | -6.65% |
| Mar 31, 2025 | 10.56% |
| Dec 31, 2024 | -25.07% |
| Sep 30, 2024 | 2.29% |
| Jun 30, 2024 | 45.12% |
| Mar 31, 2024 | 25.50% |
| Dec 31, 2023 | -11.98% |
| Sep 30, 2023 | 21.78% |
| Jun 30, 2023 | 39.86% |
| Mar 31, 2023 | 36.56% |
| Dec 31, 2022 | 14.26% |
| Sep 30, 2022 | 25.77% |
| Jun 30, 2022 | 24.61% |
| Mar 31, 2022 | 16.37% |
| Dec 31, 2021 | 63.55% |
| Sep 30, 2021 | 17.92% |